Sign in
TerminatedPhase 2

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Key facts

Who runs it
Quanli Gao
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
9 people enrolled
Started
1 Jul 2021
Ended
2 Jul 2024
Type of study
Interventional
Treatments tested
  • Tislelizumab
Record updated
3 July 2024
Why it stopped
Slow enrollment

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Pathological confirmed melanoma 2. Advanced stage confirmed by radiological examination 3. Untreated 4. ECOG PS 0-1 6. Good organ function 7. No other severe diseases such as autoimmune disease, organ transplant, chronic infection
  • Other tumor disease

Who cannot take part

  • Sensitive to drug or ingredients
  • Active infection
  • Active HBV or HCV infection
  • HIV infection
  • Autoimmune disease
  • Severe mental disorders
  • Sever disfunction of heart, liver and kidney
  • Symptomatic brain metastases

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main purpose of this study is to evaluate the safety and effectiveness of liquid tumor infiltrating lymphocytes (L-TIL) combined with tislelizumab as the first-line treatment in patients with advanced malignant melanoma. This study plan to include stage III or IV unresectable or metastatic cutaneous or acral malignant melanoma patients, treat with L-TIL 4 cycles with each infusion (3 -10) x10*9/m2 cells, combined with tislelizumab 200mg, iv, Q3W. It is expected that 30 patients will be enrolled in this study.

The group in the trial

  • L-TIL and TislelizumabTreatment being tested

    L-TIL(3-10)x10\*9/m2, Q3W, 4 cycles Tislelizumab 200mg, iv, Q3W, 1 year

    Treatment: Tislelizumab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 July 2024